GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » Centene Corp (NYSE:CNC) » Definitions » Debt-to-EBITDA

Centene (Centene) Debt-to-EBITDA : 9.04 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Centene Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Centene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $287 Mil. Centene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $18,590 Mil. Centene's annualized EBITDA for the quarter that ended in Dec. 2023 was $2,088 Mil. Centene's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 9.04.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Centene's Debt-to-EBITDA or its related term are showing as below:

CNC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.44   Med: 3.2   Max: 5.94
Current: 3.35

During the past 13 years, the highest Debt-to-EBITDA Ratio of Centene was 5.94. The lowest was 1.44. And the median was 3.20.

CNC's Debt-to-EBITDA is ranked worse than
86.67% of 15 companies
in the Healthcare Plans industry
Industry Median: 2.47 vs CNC: 3.35

Centene Debt-to-EBITDA Historical Data

The historical data trend for Centene's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centene Debt-to-EBITDA Chart

Centene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.11 3.53 5.94 5.26 3.36

Centene Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.41 2.82 2.78 3.74 9.04

Competitive Comparison of Centene's Debt-to-EBITDA

For the Healthcare Plans subindustry, Centene's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Centene's Debt-to-EBITDA Distribution in the Healthcare Plans Industry

For the Healthcare Plans industry and Healthcare sector, Centene's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Centene's Debt-to-EBITDA falls into.



Centene Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Centene's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(287 + 18590) / 5616
=3.36

Centene's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(287 + 18590) / 2088
=9.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Centene  (NYSE:CNC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Centene Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Centene's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Centene (Centene) Business Description

Address
7700 Forsyth Boulevard, Centene Plaza, St. Louis, MO, USA, 63105
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
Executives
Lori Jean Robinson director 5875 LANDERBROOK DRIVE, SUITE 220, CLEVELAND OH 44124
Andrew Lynn Asher officer: EVP, CFO 8735 HENDERSON ROAD, TAMPA FL 33634
James E Murray officer: EVP, Chief Transform. Officer 500 WEST MAIN STREET, LOUISVILLE KY 40202
Samuels Theodore R. Ii director 1990 E. GRAND AVE., EL SEGUNDO CA 90245
Monte E Ford director C/O AKAMAI TECHNOLOGIES, INC., 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Kenneth J Fasola officer: EVP, Health Care Enterprises 500 WEST MAIN STREET, LOUISVILLE KY 40202
Shannon Bagley officer: EVP, Chief Admin. Officer 7700 FORSYTH BOULEVARD, CLAYTON MO 63105
Richard A Gephardt director 822 CAPITOL SQUARE PLACE, SW, WASHINGTON DC 20024
Christopher J Coughlin director
H James Dallas director 127 PUBLIC SQUARE, CLEVELAND OH 44114
Mark J Brooks officer: SVP, Chief Information Officer 7700 FORSYTH BOULEVARD, ST. LOUIS MO 63105
David P Thomas officer: EVP, MARKETS 7700 FORSYTH BOULEVARD, ST. LOUIS MO 63105
Leslie V Norwalk director C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Wayne S Deveydt director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Toney Colin A officer: EVP, Mergers & Acquisitions 7700 FORSYTH BOULEVARD, ST. LOUIS MO 63105